Noradrenergic and Serotonergic Dysfunction in the Affective Disorders

  • Larry J. Siever
  • Emil F. Coccaro
  • Richard Friedman
  • Karen Rubinstein
  • Kenneth L. Davis


The catecholaminergic system1 and the indoleaminergic system2 have been postulated to be abnormal in the affective disorders. Considerable support exists for at least some disturbance in these systems in a substantial proportion of affective disorder patients. The exact character of these abnormalities remains to be determined. However, abnormalities in noradrenergic metabolites in body fluids3 as well as abnormalities in adrenergic receptor responsiveness4 have been found in depressed patients. Decreased concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA)5 and prolactin responses to serotonergic challenges6,7 have also been demonstrated in patients with major depressive disorder.


Affective Disorder Remit State Prolactin Response Serotonergic Receptor Serotonin Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509–522.PubMedGoogle Scholar
  2. 2.
    Murphy DL, Campbell LC, Costa JL. The brain serotonergic system in the affective disorders. Prog Neuropsychopharmacol 1978; 2: 1–31.CrossRefGoogle Scholar
  3. 3.
    Koslow JJ, Maas JW, Bowden CL, et al. CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry 1983; 40: 999–1010.PubMedGoogle Scholar
  4. 4.
    Siever LJ, Uhde TW: New studies and perspectives on the noradrenaline receptor system in depression: effects of the alpha-adrenergic agonist clonidine. Biol Psychiatry 1984; 190: 131–156.Google Scholar
  5. 5.
    Van Praag HM. Neurotransmitters and CNS disease. Lancet 1982; 2: 1259–1264.PubMedGoogle Scholar
  6. 6.
    Siever LJ, Murphy DL, Slater S, et al. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984; 34: 1029–1039.PubMedCrossRefGoogle Scholar
  7. 7.
    Heninger GR, Charney DS, Sternberg DE: Serotonergic function in depression. Arch Gen Psychiatry 1984; 41: 398–402.PubMedGoogle Scholar
  8. 8.
    Pickar D, Sweeney DR, Maas JW, et al: Primary affective disorder, clinical state change and MHPG excretion: a longitudinal study. Arch Gen Psychiatry 1978; 35: 1378–1381.PubMedGoogle Scholar
  9. 9.
    Asberg M, Thoren P, Traskman L, et al: “Serotonin depression”—a biochemical subgroup within the affective disorders? Science 1976; 191: 478–480.PubMedCrossRefGoogle Scholar
  10. 10.
    Siever LJ, Coccaro EF, Benjamin E, et al. Adrenergic and serotonergic receptor responsiveness in depression. In: Depression, Antidepressants and Receptor Sensitivity. CIBA Foundation Symposium 123 Chichester UK: John Wiley & Sons, Ltd. 1986; 148–169.Google Scholar
  11. 11.
    Hoehe M, Valido G, Matussek N. Growth hormone response to clonidine in endogenous depressive patients: evidence for a trait marker in depression. In Shagass C, et al (eds): Proceedings of the World Congress of Biologic Psychiatry. New York: Elsevier, 1986.Google Scholar
  12. 12.
    Siever LJ, Davis KL. Overview: towards a dysregulation hypothesis of depression. Am J Psychiatry 1985; 142: 1017–1031.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Larry J. Siever
  • Emil F. Coccaro
  • Richard Friedman
  • Karen Rubinstein
  • Kenneth L. Davis

There are no affiliations available

Personalised recommendations